A ligand controlled catalytic system for the aerobicoxidation of 1[degree] amines to nitriles and imines has been developed where the varying [small pi]-acidic feature of BIAN versus phen in the frameworks of ruthenium catalysts facilitates switchable selectivity.
General and selective synthesis of primary amines using Ni-based homogeneous catalysts
作者:Kathiravan Murugesan、Zhihong Wei、Vishwas G. Chandrashekhar、Haijun Jiao、Matthias Beller、Rajenahally V. Jagadeesh
DOI:10.1039/d0sc01084g
日期:——
Ni-triphos complex as the first Ni-based homogeneous catalyst for both reductive amination of carbonyl compounds with ammonia and hydrogenation of nitroarenes to prepare all kinds of primary amines. Remarkably, this Ni-complex enabled the synthesis of functionalized and structurally diverse benzylic, heterocyclic and aliphatic linear and branched primary amines as well as aromatic primary amines starting
chemo‐enzymatic aerobic oxidation in water of benzylamines to obtain aldehydes or imines is described. Laccasefrom Trametes versicolor was chosen as biocatalyst, and TEMPO (radical 2,2,6,6‐tetramethylpiperidine 1‐oxyl) as mediator. A study on the pH dependence of the aqueousmedium allowed us to realise a fine tuning on product selectivity. Under our optimized reaction conditions, the bio‐oxidation
A dehydrogenation of primaryamine to give the corresponding nitrileunder oxidant- and base-free conditionscatalysed by simple [Ru(p-cym)Cl2 ]2 with no extra ligand is reported. The system is highly selective for alkyl amines, whereas benzylamine derivatives gave the nitrile product together with the imine in a ratio ranging from 14:1 to 4:1 depending on the substrate. Preliminary mechanistic investigations
[EN] COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES SUCH AS ALZHEIMER'S DISEASE, TYPE 2 DIABETES, AND PARKINSON'S DISEASE<br/>[FR] COMPOSES, COMPOSITIONS ET PROCEDES DE TRAITEMENT DE MALADIES AMYLOIDES ET DE SYNUCLEINOPATHIES, NOTAMMENT DE LA MALADIE D'ALZHEIMER, DU DIABETE DE TYPE 2 ET DE LA MALADIE DE PARKINSON
申请人:PROTEOTECH INC
公开号:WO2003101927A1
公开(公告)日:2003-12-11
Bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs and pharmaceutically acceptable esters, their synthesis, pharmaceutical compositions containing them, and their use in the treatment of amyloid diseases, especially Aß amyloidosis, such as observed in Alzheimer's disease, IAPP amyloidosis, such as observed in type 2 diabetes, and synucleinophathies, such as observed in Parkinson's disease, and the manufacture of medicaments for such treatment.